Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Dentsply Sirona Inc. (XRAY), a leading company in the dental equipment and supplies industry with a market capitalization of $3.44 billion, has seen its stock price descend to a 52-week low, reaching $17.19. According to InvestingPro analysis, the stock appears undervalued at current levels. This price level reflects a significant downturn for the company, which has experienced a substantial 1-year change with a decline of -48.05%. Despite current challenges, the company maintains a strong 3.4% dividend yield and has maintained dividend payments for 31 consecutive years. While not profitable over the last twelve months, InvestingPro analysis indicates expected profitability this year, with analysts forecasting positive earnings. Investors are closely monitoring the stock as it navigates through this challenging period, with stakeholders looking for strategies that might reverse the downward trend and restore confidence in XRAY’s market position. For deeper insights, access the comprehensive Pro Research Report available on InvestingPro, covering what really matters about XRAY’s financial health and future prospects.
In other recent news, Dentsply Sirona Inc. reported its fourth-quarter 2024 earnings, which presented a mixed financial performance. The company slightly exceeded earnings per share (EPS) expectations with an EPS of $0.44, just above the forecast of $0.43. However, revenue fell short, coming in at $905 million compared to the anticipated $922.82 million, highlighting ongoing challenges in the dental market. The company experienced a 10.6% decline in reported sales for the quarter and a 4.3% decrease in full-year sales, reaching $3.79 billion.
Dentsply Sirona is actively exploring strategic alternatives for its Wellspect Healthcare business, a move that could potentially unlock significant value for stakeholders. The company remains focused on digital dentistry as a growth area, emphasizing new product launches and increased user engagement. Despite the revenue miss, the company reported an operating cash flow of $461 million, marking a 22.3% increase year-over-year. Analysts from firms like Evercore ISI and Morgan Stanley (NYSE:MS) have noted the company’s strategic initiatives and cost structure optimizations aimed at supporting future growth.
Looking ahead, Dentsply Sirona projects an organic sales decline of 2-4% for 2025 and anticipates an EBITDA margin exceeding 18%. The company expects adjusted EPS between $1.80 and $2.00, with continued growth in its SureSmile and Wellspect product lines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.